Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.
Press releases published on April 22, 2025
Mitolyn Reviews: Ingredients, Benefits, Pros and Cons! Honest Analysis Inside!
GlobeNewswire
·
April 22, 2025
Albany, New York, April 22, 2025 (GLOBE NEWSWIRE) -- If you're struggling with stubborn weight, low energy, or slow metabolism, Mitolyn might be the breakthrough you've been waiting for. Touted as a cutting-edge mitochondrial support supplement, Mitolyn is …
Mitolyn Reviews (Investigative Warning 2025): A Comprehensive Review of the Revolutionary Mitochondrial and Cellular Health Supplement
GlobeNewswire
·
April 22, 2025
New York City, April 22, 2025 (GLOBE NEWSWIRE) -- The recent energy drops together with slowing metabolic processes and cognitive decline present a common problem that the pioneering solution Mitolyn addresses to rejuvenate cellular health alongside …
UPDATE -- AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting
GlobeNewswire
·
April 22, 2025
TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced that it will present a preclinical abstract in …
UPDATE -- Opreme Films announces “Just Blood”: A Medical Demonstration Poised to Rewrite Theranos Story
GlobeNewswire
·
April 22, 2025
MIAMI BEACH, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- In a moment destined to shake the foundation of modern medicine—and perhaps the U.S. justice system—visionary medical innovator Ryan El-Hosseiny is making a bold and unprecedented claim: Elizabeth …
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China
GlobeNewswire
·
April 22, 2025
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in …
Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal
GlobeNewswire
·
April 22, 2025
San Antonio, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice from the NYSE …